12,372 trials
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Primary Immunodeficiency · Agammaglobulinemia · Hypogammaglobulinemia
Primary: Incidence of Acute, Serious Bacterial Infections in the Total ITT Population. — 0.04 ASBI's/person-year
Hypoglycemia · Diabetes Mellitus, Type 1
Primary: Percentage of Patients With ADA — 0; 0; 56; 54 Participants
Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Primary: Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score — .7971 proportion of subjects
Lung Neoplasms
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) — 8.9; 5.0…
Cataract
Primary: Cure at Day 14 — 94; 97; 24; 50 Participants — p=0.0005
Type 2 Diabetes Mellitus
Primary: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke])…
Influenza
Primary: Number of Participants Reporting Solicited Injection Site (Local) Reactions — 1421; 2050; 797; 177 Participants
Migraine Headache
Primary: Number of Participants With Serious Adverse Events (SAEs) — 5; 3 Participants
Fuchs' Endothelial Dystrophy · Bullous Keratopathy
Primary: Intraocular Pressure — 11; 18 Participants
Relapsing Multiple Sclerosis
Primary: Adjusted Annualized Relapse Rate (ARR) at the End of Month 24 — 0.276; 0.218; 0.172 relapses/year — p=<0.0001
Relapsing Multiple Sclerosis
Primary: Total Number of Gadolinium-Enhancing (GdE) Lesions Assessed on Brain Magnetic Resonance Imaging (MRI) From Week 12 to Week 24 — 11.1; 1.9; 1.5 lesions — p=<0.0001
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Specific Image-based Airway Volume (siVaw) — 1.72; 1.53 Ratio to baseline — p=<0.0001
Posttraumatic Stress Disorder (PTSD)
Primary: Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) — 22.5; 33.2 score on a scale
Short Bowel Syndrome
Primary: Absolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data — -11.8; -26.2 mL/kg/day